


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds of the~~ A compound of formula I:



in which:

~~n is an integer chosen from 1, 2 and 3~~ 1;

Y represents O; N-OR⁹, in which R⁹ represents H or a saturated hydrocarbon-based aliphatic group; CR¹⁰R¹¹, in which R¹⁰ and R¹¹, which may be identical or different, represent H or a saturated hydrocarbon-based aliphatic group;

R¹ and R², which may be identical or different, represent H or a saturated aliphatic hydrocarbon-based chain; or alternatively R¹ and R² together form an optionally substituted saturated aliphatic hydrocarbon-based chain;

~~the radicals R³ and R⁴, which may be identical or different, take any of the meanings given above for R¹ and R², or alternatively~~

R¹ and ~~the group~~ R⁴ borne by the carbon alpha to CR¹R² represent nothing and a double bond links the CR¹R² carbon to the alpha CR³R⁴ carbon; or alternatively

one of ~~the radicals~~ R¹ and R² forms with one of ~~the radicals~~ R³ and R⁴ an optionally substituted saturated or unsaturated aliphatic hydrocarbon-based chain;

one of ~~the radicals~~ R⁵ and R⁶ represents W, and the other represents Z₁, which is ~~chosen from~~ a saturated or unsaturated aliphatic hydrocarbon-based radical; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic or heterocyclic radical; a radical -alk-Cy, in which alk represents an alkylene chain and Cy represents an optionally substituted saturated, unsaturated and/or aromatic heterocyclic or carbocyclic radical;

W represents -XL-CO₂R⁷; ~~X-L-Tet, in which X and L are as defined below and Tet represents optionally substituted tetrazole; in which~~

L represents a saturated or unsaturated aliphatic hydrocarbon-based chain, which is optionally substituted and/or optionally interrupted by optionally substituted arylene;

X represents O; NR^8 , in which R^8 represents H; a saturated aliphatic hydrocarbon-based group; a group $-\text{CO}-\text{R}'$ or $-\text{SO}_2-\text{R}'$, in which R' takes any of the meanings given below for R^7 with the exception of H; or R^8 represents an optionally substituted aromatic carbocyclic group; or X represents $\text{S}(\text{O})_m$, in which m is ~~chosen from 0, 1 and 2~~ 0, 1 or 2;

R^7 represents H; a saturated or unsaturated aliphatic hydrocarbon-based group; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic group; an optionally substituted, saturated, unsaturated and/or aromatic heterocyclic group; ~~and the or a pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, and also mixtures thereof in all proportions salt, or solvate thereof.~~

2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterized in that wherein~~ R^1 , R^2 , R^3 and R^4 are independently ~~chosen from~~ a hydrogen atom and or alkyl.


3. (Cancelled)

4. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterised in that wherein~~ R^7 represents H or alkyl.

5. (Cancelled)


6. (Currently Amended) ~~Compound~~ A compound according to Claim 1, ~~characterised in that wherein~~ L represents alkylene, alkenylene or $-\text{alk}^\circ-\text{Ar}^\circ$, in which alk° represents alkylene and Ar° represents optionally substituted phenylene.

7. (Currently Amended) ~~Compounds~~ A compound according to Claim 6, ~~characterised in that wherein~~ L represents



8. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterised in that wherein~~ Z represents alkyl optionally substituted by one or more radicals T; alkenyl optionally substituted by one or more radicals T; alkynyl optionally substituted by one or more radicals T; phenyl optionally substituted by one or more radicals T; cycloalkyl optionally substituted by one or more radicals T; monocyclic or bicyclic heteroaryl optionally substituted by one or more radicals T; -alk¹-Cy¹, in which alk¹ represents alkylene, preferably CH₂ and Cy¹ represents phenyl optionally substituted by one or more radicals T, or alternatively Cy¹ represents cycloalkyl, optionally substituted by one or more radicals T; T ~~being chosen from~~ is an optionally halogenated alkyl; optionally halogenated alkoxy; a halogen atom; ~~and~~ or cyano.

9. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~characterised in that n=1; wherein~~ R¹, R², R³ and R⁴ represent a hydrogen atom; Y represents O; R⁵ represents (C₁-C₁₀)alkyl; (C₂-C₁₀)alkynyl; -alk¹-Cy¹, in which alk¹ represents (C₁-C₃)alkylene and Cy¹ represents phenyl optionally substituted by one or more radicals T, in which T is an optionally halogenated alkyl; optionally halogenated alkoxy; a halogen atom; or cyano



; R⁶ represents W, in which X represents O or NH; and L represents (C₁-C₃)alkylene.









10. (Currently Amended) ~~Compounds~~ A compound according to Claim 8, ~~characterised in that wherein~~ X represents NH; and R⁵ represents (C₁-C₁₀)alkyl.

11. (Currently Amended) ~~Compounds~~ A compound according to Claim 8, ~~characterised in that wherein~~ X represents O; and R⁵ represents (C₁-C₁₀)alkyl; (C₂-C₁₀)alkynyl; ~~and~~ or -alk¹-Cy¹, in which alk¹ represents (C₁-C₃)alkylene and Cy¹ represents phenyl.

12. (Currently Amended) ~~Compounds~~ A compound according to Claim 8, ~~characterised in that wherein~~ Z represents alkyl, optionally substituted by cyano; phenyl, optionally substituted by trifluoromethyl, with halogen, with alkyl or with alkoxy; phenylalkyl, in

which phenyl is substituted by one or more halogen atoms, alkyl or alkoxy; alkynyl; or cycloalkylalkyl.

13. (Currently Amended) Compounds A compound according to Claim 1, ~~chosen from which is one of the following compounds~~



~~and the or a pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, and also mixtures thereof in all proportions salt, or solvate thereof.~~

14. (Currently Amended) Pharmaceutical A pharmaceutical composition comprising an ~~effective amount of at least one compound chosen from the compounds of the~~ a compound of formula I according to Claim 1 and/or the pharmaceutically acceptable


derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions, in combination with at least one and a pharmaceutically acceptable vehicle.

15. (Cancelled)

16. (Currently Amended) ~~Use of a compound of the formula I according to Claim 1 and/or the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions, for the preparation of a medicament~~ A method for the treatment of an individual suffering from a disease or condition mediated by an insufficiency of activity of the PPAR α and PPAR γ isoforms in their role of regulating lipidaemia and glycaemia comprising administering to said individual an effective amount of a pharmaceutical composition according to claim 14.

17. (Currently Amended) ~~Use, according to Claim 16, of compounds of the formula I and/or the physiologically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions, for the preparation of a medicament for the prevention of or~~ A method for treating dyslipidaemia, atherosclerosis and or diabetes comprising administering a subject in need thereof an effective amount of a pharmaceutical composition according to claim 14.


18. (Currently Amended) ~~Process for the preparation of a compound of the~~ A process for preparing a compound of formula I according to Claim 1, characterised in that comprising reacting a compound of the formula II:



in which


R¹, R², R³, R⁴, n and Y are as defined above for formula I, G represents -XH, in which X is S or O, NHCOF₃ or NHR⁸, R⁸ being as defined for formula I in Claim 1; and Z° is a radical

that is a precursor of Z, or alternatively Z^o represents Z, Z being as defined for formula I in Claim 1, Z^o and G being in positions 2 and 3 of the phenyl nucleus;
is reacted with a compound of the formula III:



in which R⁷ and L are as defined in Claim 1 for formula I and Gp represents a leaving group, in the presence of a base.

19. (Currently Amended) ~~Process for the preparation of a compound of the~~
A process for preparing a compound of formula I according to Claim 1, in which Z represents
Cy, in which Cy denotes an optionally substituted aryl or heteroaryl group, ~~characterised in~~
~~that it comprises the reaction of a compound of the~~
comprising reacting a compound of formula IVa:




in which D represents -NHCOCF₃ or -X-L-CO₂R⁷, and L, R⁷, Y, X, R¹, R², R³, R⁴ and n are as defined for formula I in Claim 1, and Hal represents a halogen atom, ~~preferably a bromine or iodine atom, the groups -Hal and D being~~ in position 2 or 3, with an arylboronic or heteroarylboronic acid of the formula V:



in which ~~the group~~ Cy optionally bears one or more substituents, in the presence of a palladium 0 complex and a mineral or organic base.


20. (Currently Amended) ~~Process for the preparation of a compound of the~~ A
process for preparing a compound of formula I according to Claim 1, in which Z represents -
CH₂-π, in which π represents alkyl; alkenyl; alkynyl; Cy¹, wherein Cy¹ being is as defined for Cy

in Claim 1 for formula I; or $-\text{alk}^2-\text{Cy}^1$, wherein alk^2 representing represents alkylene and Cy^1 being is as defined above, the said process being characterised in that comprising reacting a compound of the formula IVa:



in which $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{n}, \text{Y}, \text{X}, \text{L}, \text{R}^7$ and D are as defined in Claim 18

in which D represents $-\text{NHCOCF}_3$ or $-\text{X}-\text{L}-\text{CO}_2\text{R}^7$, and $\text{L}, \text{R}^7, \text{Y}, \text{X}, \text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4$ and n are as defined for formula I, and Hal represents a halogen atom, preferably an iodine or bromine atom, $-\text{Hal}$ and D being in position 2 or 3, is reacted with a compound of the formula VII



in which π is as defined above,

in the presence of a palladium complex, such as bis(triphenylphosphine)dichloropalladium.

21. (Currently Amended) Process for the preparation of a compound of the A process for preparing a compound of formula I according to Claim 1 in which Y represents $\text{N}-\text{OH}$, characterised in that it comprises the reaction of the corresponding compound of the comprising reacting a compound of formula I in which $\text{Y} = \text{O}$ with a hydroxylamine salt in the presence of an alkali metal salt.


22. (Currently Amended) Process for the preparation of a compound of the A process for preparing a compound of formula I in which Y represents $\text{CR}^{10}\text{R}^{11}$, in which R^{10} and R^{11} are as defined in Claim 1, characterised in that the corresponding compound of the for formula I, comprising reacting a compound of formula I in which Y represents O is reacted with a compound of the formula IX



in the presence of a base.

23 - 30. (Cancelled)

31. (New) A compound of formula I:



in which:

n is 1;

Y represents O; N-OR⁹, in which R⁹ represents H or a saturated hydrocarbon-based aliphatic group; CR¹⁰R¹¹, in which R¹⁰ and R¹¹, which may be identical or different, represent H or a saturated hydrocarbon-based aliphatic group;

R¹ and R², which may be identical or different, represent H or a saturated aliphatic hydrocarbon-based chain; or alternatively R¹ and R² together form an optionally substituted saturated aliphatic hydrocarbon-based chain;

R³ and R⁴, which may be identical or different, take any of the meanings given above for R¹ and R², or alternatively

R¹ and R⁴ borne by the carbon alpha to CR¹R² represent nothing and a double bond links the CR¹R² carbon to the alpha CR³R⁴ carbon; or alternatively

one of R¹ and R² forms with one of R³ and R⁴ an optionally substituted saturated or unsaturated aliphatic hydrocarbon-based chain;

one of R⁵ and R⁶ represents W, and the other represents Z, which is a saturated or unsaturated aliphatic hydrocarbon-based radical; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic or heterocyclic radical; a radical -alk-Cy, in which alk represents an alkylene chain and Cy represents an optionally substituted saturated, unsaturated and/or aromatic heterocyclic or carbocyclic radical;

W represents -XL-CO₂R⁷;









L represents a saturated or unsaturated aliphatic hydrocarbon-based chain, which is optionally

substituted and/or optionally interrupted by optionally substituted arylene;

X represents O; NR⁸, in which R⁸ represents H; a saturated aliphatic hydrocarbon-based group; a group -CO-R' or -SO₂-R', in which R' takes any of the meanings given below for R⁷ with the exception of H; or R⁸ represents an optionally substituted aromatic carbocyclic group; or X represents S(O)_m, in which m is 0, 1 or 2;

R⁷ represents H; a saturated or unsaturated aliphatic hydrocarbon-based group; an optionally substituted, saturated, unsaturated and/or aromatic carbocyclic group; an optionally substituted, saturated, unsaturated and/or aromatic heterocyclic group; or a pharmaceutically acceptable salt thereof.

32. (New) A compound according to Claim 31, which is one of the following compounds



or a pharmaceutically acceptable salt thereof.

33. (New) A composition comprising stereoisomers of a compound according to Claim 31.

34. (New) A composition comprising a mixture of isomers of a compound according to Claim 31.

35. (New) A composition comprising stereoisomers of a compound according to Claim 32.

36. (New) A composition comprising a mixture of isomers of a compound according to Claim 32.

37. (New) A pharmaceutical composition comprising a compound of formula I according to Claim 31 and a pharmaceutically acceptable vehicle.

38. (New) A method for the treatment of an individual suffering from a disease or condition mediated by an insufficiency of activity of the PPAR α and PPAR γ isoforms in their role of regulating lipidaemia and glycaemia comprising administering to said individual an effective amount of a pharmaceutical composition according to claim 37.

39. (New) A method for treating dyslipidaemia, atherosclerosis or diabetes comprising administering a subject in need thereof an effective amount of a pharmaceutical composition according to claim 37.

40. (New) A pharmaceutical composition comprising a compound of formula I according to Claim 32 and a pharmaceutically acceptable vehicle.